P513S News

Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial

PALO ALTO, Calif., March 12 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late stage biotechnology company...

Avicena Group to Present at 10th Annual BIO CEO & Investor Conference

PALO ALTO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology company...

WallSt.net Announces Upcoming Interview With CEO of Avicena Group

NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- Dr. Belinda Tsao-Nivaggioli, Chief Executive Officer of Avicena Group, Inc. (OTC:AVGO) (BULLETIN...

Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclero

Selected Therapy Can Advance to Phase III Clinical Trial PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO...

Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease

PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTCBB: AVGO), a late-stage biotechnology company that develops central...

USPTO Issues Patent for Avicena Group's Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis

Patent Expands Existing IP to Treat ALS PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD:...

Avicena to Present at 9th Annual Acumen BioFin Healthcare Conference

PALO ALTO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology company...

Avicena Announces the Commercial Launch of Its Nurigene(TM) Anti-Aging Skin Care Regimen

PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a developer of novel pharmaceutical...

Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium

PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology company...

Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds

PALO ALTO, Calif., Aug. 28 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology company...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

P513S (P513S)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial

Avicena Group to Present at 10th Annual BIO CEO & Investor Conference

WallSt.net Announces Upcoming Interview With CEO of Avicena Group

Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclero

Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease

USPTO Issues Patent for Avicena Group's Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis

Avicena to Present at 9th Annual Acumen BioFin Healthcare Conference

Avicena Announces the Commercial Launch of Its Nurigene(TM) Anti-Aging Skin Care Regimen

Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium

Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors

Avicena to Present at 4th Annual BIO InvestorForum Conference

Avicena Appoints Dr. M. Flint Beal to Board of Directors

Avicena Group Announces Closing of Private Offering

Avicena Reports Second Quarter 2007 Results

Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds

P513S Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

P513S (P513S) News

P513S (P513S)

Empower your portfolio: Real-time discussions and actionable trading ideas.

P513S News

Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial

Avicena Group to Present at 10th Annual BIO CEO & Investor Conference

WallSt.net Announces Upcoming Interview With CEO of Avicena Group

Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclero

Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease

USPTO Issues Patent for Avicena Group's Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis

Avicena to Present at 9th Annual Acumen BioFin Healthcare Conference

Avicena Announces the Commercial Launch of Its Nurigene(TM) Anti-Aging Skin Care Regimen

Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium

Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors

Avicena to Present at 4th Annual BIO InvestorForum Conference

Avicena Appoints Dr. M. Flint Beal to Board of Directors

Avicena Group Announces Closing of Private Offering

Avicena Reports Second Quarter 2007 Results

Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds

P513S Discussion

Your Recent History